메뉴 건너뛰기




Volumn 15, Issue S, 2015, Pages S27-S33

New Therapeutic Approaches in Polycythemia Vera

Author keywords

Hydroxyurea; Interferon; JAK2; Polycythemia vera; Ruxolitinib

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; BUSULFAN; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHORUS 32; PIPOBROMAN; RUXOLITINIB; VORINOSTAT; ANTINEOPLASTIC AGENT;

EID: 84939645268     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.013     Document Type: Review
Times cited : (13)

References (80)
  • 2
    • 84878169183 scopus 로고    scopus 로고
    • Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
    • A. Tefferi Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management Am J Hematol 88 2013 507 516
    • (2013) Am J Hematol , vol.88 , pp. 507-516
    • Tefferi, A.1
  • 3
    • 17844383458 scopus 로고    scopus 로고
    • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    • C. James, V. Ugo, J.P.L. Couedic, and et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
    • (2005) Nature , vol.434 , pp. 1144-1148
    • James, C.1    Ugo, V.2    Couedic, J.P.L.3
  • 4
    • 17644424955 scopus 로고    scopus 로고
    • A gain-of-function mutation of JAK2 in myeloproliferative disorders
    • R. Kralovics, F. Passamonti, A. Buser, and et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
    • (2005) N Engl J Med , vol.352 , pp. 1779-1790
    • Kralovics, R.1    Passamonti, F.2    Buser, A.3
  • 5
    • 79551575494 scopus 로고    scopus 로고
    • Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
    • A. Quintas-Cardama, H. Kantarjian, J. Cortes, and et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond Nat Rev Drug Discov 10 2011 127 140
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 127-140
    • Quintas-Cardama, A.1    Kantarjian, H.2    Cortes, J.3
  • 6
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • S. Verstovsek, R. Mesa, J. Gotlib, and et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
    • (2012) N Engl J Med , vol.366 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.2    Gotlib, J.3
  • 7
    • 84857837774 scopus 로고    scopus 로고
    • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    • C. Harrison, J. Kiladjian, H. Al-Ali, and et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
    • (2012) N Engl J Med , vol.366 , pp. 787-798
    • Harrison, C.1    Kiladjian, J.2    Al-Ali, H.3
  • 8
    • 0026551775 scopus 로고
    • Incidence of polycythemia vera in a defined population
    • S. Berglund, and O. Zettervall Incidence of polycythemia vera in a defined population Eur J Haematol 48 1992 20 26
    • (1992) Eur J Haematol , vol.48 , pp. 20-26
    • Berglund, S.1    Zettervall, O.2
  • 9
    • 0025820104 scopus 로고
    • Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
    • C. Rozman, M. Giralt, E. Feliu, and et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders Cancer 67 1991 2658 2663
    • (1991) Cancer , vol.67 , pp. 2658-2663
    • Rozman, C.1    Giralt, M.2    Feliu, E.3
  • 10
    • 8344229870 scopus 로고    scopus 로고
    • Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
    • F. Passamonti, E. Rumi, E. Pungolino, and et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 2004 755 761
    • (2004) Am J Med , vol.117 , pp. 755-761
    • Passamonti, F.1    Rumi, E.2    Pungolino, E.3
  • 11
    • 84865193045 scopus 로고    scopus 로고
    • Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study
    • M. Hultcrantz, S.Y. Kristinsson, T.M. Andersson, and et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study J Clin Oncol 30 2012 2995 3001
    • (2012) J Clin Oncol , vol.30 , pp. 2995-3001
    • Hultcrantz, M.1    Kristinsson, S.Y.2    Andersson, T.M.3
  • 12
    • 84900866397 scopus 로고    scopus 로고
    • How common are myeloproliferative neoplasms? A systematic review and meta-analysis
    • G.J. Titmarsh, A.S. Duncombe, M.F. McMullin, and et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis Am J Hematol 89 2014 581 587
    • (2014) Am J Hematol , vol.89 , pp. 581-587
    • Titmarsh, G.J.1    Duncombe, A.S.2    McMullin, M.F.3
  • 13
    • 84896548818 scopus 로고    scopus 로고
    • Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
    • O. Moulard, J. Mehta, J. Fryzek, and et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union Eur J Haematol 92 2014 289 297
    • (2014) Eur J Haematol , vol.92 , pp. 289-297
    • Moulard, O.1    Mehta, J.2    Fryzek, J.3
  • 14
    • 33846266634 scopus 로고    scopus 로고
    • The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients
    • R.A. Mesa, J. Niblack, M. Wadleigh, and et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients Cancer 109 2007 68 76
    • (2007) Cancer , vol.109 , pp. 68-76
    • Mesa, R.A.1    Niblack, J.2    Wadleigh, M.3
  • 15
    • 20244389579 scopus 로고    scopus 로고
    • Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    • R. Marchioli, G. Finazzi, R. Landolfi, and et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2005 2224 2232
    • (2005) J Clin Oncol , vol.23 , pp. 2224-2232
    • Marchioli, R.1    Finazzi, G.2    Landolfi, R.3
  • 16
    • 79960437973 scopus 로고    scopus 로고
    • The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
    • R. Scherber, A.C. Dueck, P. Johansson, and et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients Blood 118 2011 401 408
    • (2011) Blood , vol.118 , pp. 401-408
    • Scherber, R.1    Dueck, A.C.2    Johansson, P.3
  • 17
    • 84869381382 scopus 로고    scopus 로고
    • Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
    • R.M. Emanuel, A.C. Dueck, H.L. Geyer, and et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs J Clin Oncol 30 2012 4098 4103
    • (2012) J Clin Oncol , vol.30 , pp. 4098-4103
    • Emanuel, R.M.1    Dueck, A.C.2    Geyer, H.L.3
  • 18
    • 34249949626 scopus 로고    scopus 로고
    • Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    • A. Tefferi, and M. Elliott Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F Semin Thromb Hemost 33 2007 313 320
    • (2007) Semin Thromb Hemost , vol.33 , pp. 313-320
    • Tefferi, A.1    Elliott, M.2
  • 19
    • 84883273483 scopus 로고    scopus 로고
    • Splanchnic vein thrombosis in myeloproliferative neoplasms
    • M. Sekhar, K. McVinnie, and A.K. Burroughs Splanchnic vein thrombosis in myeloproliferative neoplasms Br J Haematol 162 2013 730 747
    • (2013) Br J Haematol , vol.162 , pp. 730-747
    • Sekhar, M.1    McVinnie, K.2    Burroughs, A.K.3
  • 20
    • 67049173799 scopus 로고    scopus 로고
    • JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
    • F. Dentali, A. Squizzato, L. Brivio, and et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood 113 2009 5617 5623
    • (2009) Blood , vol.113 , pp. 5617-5623
    • Dentali, F.1    Squizzato, A.2    Brivio, L.3
  • 21
    • 84879104781 scopus 로고    scopus 로고
    • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
    • B.L. Stein, S. Saraf, U. Sobol, and et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera Leuk Lymphoma 54 2013 1989 1995
    • (2013) Leuk Lymphoma , vol.54 , pp. 1989-1995
    • Stein, B.L.1    Saraf, S.2    Sobol, U.3
  • 22
    • 84869175457 scopus 로고    scopus 로고
    • Polycythemia vera: gender-related phenotypic differences
    • R. Landolfi, L. Di Gennaro, M.A. Nicolazzi, and et al. Polycythemia vera: gender-related phenotypic differences Int Emerg Med 7 2012 509 515
    • (2012) Int Emerg Med , vol.7 , pp. 509-515
    • Landolfi, R.1    Di Gennaro, L.2    Nicolazzi, M.A.3
  • 23
    • 0036911075 scopus 로고    scopus 로고
    • Portal vein thrombosis after splenectomy
    • E.R. Winslow, L.M. Brunt, J.A. Drebin, and et al. Portal vein thrombosis after splenectomy Am J Surg 184 2002 631 636
    • (2002) Am J Surg , vol.184 , pp. 631-636
    • Winslow, E.R.1    Brunt, L.M.2    Drebin, J.A.3
  • 24
    • 33749028699 scopus 로고    scopus 로고
    • The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera
    • J.J. Michiels, Z. Berneman, W. Schroyens, and et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera Semin Thromb Hemost 32 2006 589 604
    • (2006) Semin Thromb Hemost , vol.32 , pp. 589-604
    • Michiels, J.J.1    Berneman, Z.2    Schroyens, W.3
  • 25
    • 34248364065 scopus 로고    scopus 로고
    • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
    • R.A. Mesa, S. Verstovsek, F. Cervantes, and et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Leuk Res 31 2007 737 740
    • (2007) Leuk Res , vol.31 , pp. 737-740
    • Mesa, R.A.1    Verstovsek, S.2    Cervantes, F.3
  • 26
    • 84859238493 scopus 로고    scopus 로고
    • Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
    • M.N. Kundranda, R. Tibes, and R.A. Mesa Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep 7 2012 78 86
    • (2012) Curr Hematol Malig Rep , vol.7 , pp. 78-86
    • Kundranda, M.N.1    Tibes, R.2    Mesa, R.A.3
  • 27
    • 84887345428 scopus 로고    scopus 로고
    • Myeloproliferative neoplasms and thrombosis
    • T. Barbui, G. Finazzi, and A. Falanga Myeloproliferative neoplasms and thrombosis Blood 122 2013 2176 2184
    • (2013) Blood , vol.122 , pp. 2176-2184
    • Barbui, T.1    Finazzi, G.2    Falanga, A.3
  • 28
    • 0018181405 scopus 로고
    • Vascular occlusive episodes and venous haematocrit in primary myeloproliferative polychytemia
    • T.C. Pearson, and G. Wetherley-Mein Vascular occlusive episodes and venous haematocrit in primary myeloproliferative polychytemia Lancet 2 1978 1219 1222
    • (1978) Lancet , vol.2 , pp. 1219-1222
    • Pearson, T.C.1    Wetherley-Mein, G.2
  • 29
    • 33947208087 scopus 로고    scopus 로고
    • Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
    • R. Landolfi, L. Di Gennaro, T. Barbui, and et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood 109 2007 2446 2452
    • (2007) Blood , vol.109 , pp. 2446-2452
    • Landolfi, R.1    Di Gennaro, L.2    Barbui, T.3
  • 30
    • 84883742082 scopus 로고    scopus 로고
    • Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
    • A. Tefferi, E. Rumi, G. Finazzi, and et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study Leukemia 27 2013 1874 1881
    • (2013) Leukemia , vol.27 , pp. 1874-1881
    • Tefferi, A.1    Rumi, E.2    Finazzi, G.3
  • 31
    • 79551607979 scopus 로고    scopus 로고
    • Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
    • F. Passamonti, C. Elena, S. Schnittger, and et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations Blood 117 2011 2813 2816
    • (2011) Blood , vol.117 , pp. 2813-2816
    • Passamonti, F.1    Elena, C.2    Schnittger, S.3
  • 32
    • 0000520406 scopus 로고
    • Effect of therapy on blood volume, blood pressure, and splen size in polycythemia vera
    • T.C. Prentice, N.I. Berlin, and J.H. Lawrence Effect of therapy on blood volume, blood pressure, and splen size in polycythemia vera Arch Intern Med 89 1952 584 590
    • (1952) Arch Intern Med , vol.89 , pp. 584-590
    • Prentice, T.C.1    Berlin, N.I.2    Lawrence, J.H.3
  • 33
    • 79551491928 scopus 로고    scopus 로고
    • Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
    • T. Barbui, G. Barosi, G. Birgegard, and et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet J Clin Oncol 29 2011 761 770
    • (2011) J Clin Oncol , vol.29 , pp. 761-770
    • Barbui, T.1    Barosi, G.2    Birgegard, G.3
  • 34
    • 0022743990 scopus 로고
    • Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
    • A.P. Tartaglia, J.D. Goldberg, P.D. Berk, and et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera Semin Hematol 23 1986 172 176
    • (1986) Semin Hematol , vol.23 , pp. 172-176
    • Tartaglia, A.P.1    Goldberg, J.D.2    Berk, P.D.3
  • 35
    • 0028354308 scopus 로고
    • Aspirin as an antiplatelet drug
    • C. Patrono Aspirin as an antiplatelet drug N Engl J Med 330 1994 1287 1294
    • (1994) N Engl J Med , vol.330 , pp. 1287-1294
    • Patrono, C.1
  • 36
    • 84983134916 scopus 로고    scopus 로고
    • Low-dose aspirin in polycythaemia vera: a pilot study
    • GISP. Low-dose aspirin in polycythaemia vera: a pilot study Br J Haematol 97 1997 453 456
    • (1997) Br J Haematol , vol.97 , pp. 453-456
    • GISP1
  • 37
    • 0346727336 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose aspirin in polycythemia vera
    • R. Landolfi, R. Marchioli, J. Kutti, and et al. Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2004 114 124
    • (2004) N Engl J Med , vol.350 , pp. 114-124
    • Landolfi, R.1    Marchioli, R.2    Kutti, J.3
  • 38
    • 0017371237 scopus 로고
    • Cerebral blood-flow in polycythaemia
    • D.J. Thomas, G.H. du Boulay, J. Marshall, and et al. Cerebral blood-flow in polycythaemia Lancet 2 1977 161 163
    • (1977) Lancet , vol.2 , pp. 161-163
    • Thomas, D.J.1    Du Boulay, G.H.2    Marshall, J.3
  • 39
    • 0022703490 scopus 로고
    • Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
    • P.D. Berk, J.D. Goldberg, P.B. Donovan, and et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols Semin Hematol 23 1986 132 143
    • (1986) Semin Hematol , vol.23 , pp. 132-143
    • Berk, P.D.1    Goldberg, J.D.2    Donovan, P.B.3
  • 40
    • 84871746842 scopus 로고    scopus 로고
    • Cardiovascular events and intensity of treatment in polycythemia vera
    • R. Marchioli, G. Finazzi, G. Specchia, and et al. Cardiovascular events and intensity of treatment in polycythemia vera N Engl J Med 368 2013 22 33
    • (2013) N Engl J Med , vol.368 , pp. 22-33
    • Marchioli, R.1    Finazzi, G.2    Specchia, G.3
  • 41
    • 66549086134 scopus 로고    scopus 로고
    • Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
    • G. Barosi, G. Birgegard, G. Finazzi, and et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference Blood 113 2009 4829 4833
    • (2009) Blood , vol.113 , pp. 4829-4833
    • Barosi, G.1    Birgegard, G.2    Finazzi, G.3
  • 42
    • 84856866188 scopus 로고    scopus 로고
    • Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
    • A. Alvarez-Larran, A. Pereira, F. Cervantes, and et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera Blood 119 2012 1363 1369
    • (2012) Blood , vol.119 , pp. 1363-1369
    • Alvarez-Larran, A.1    Pereira, A.2    Cervantes, F.3
  • 43
    • 84881065384 scopus 로고    scopus 로고
    • Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
    • G. Barosi, R. Mesa, G. Finazzi, and et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project Blood 121 2013 4778 4781
    • (2013) Blood , vol.121 , pp. 4778-4781
    • Barosi, G.1    Mesa, R.2    Finazzi, G.3
  • 44
    • 84876138022 scopus 로고    scopus 로고
    • Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms
    • B.L. Stein, and R.V. Tiu Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms J Interferon Cytokine Res 33 2013 145 153
    • (2013) J Interferon Cytokine Res , vol.33 , pp. 145-153
    • Stein, B.L.1    Tiu, R.V.2
  • 45
    • 0018098799 scopus 로고
    • Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth
    • F. Balkwill, and J. Taylor-Papadimitriou Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth Nature 274 1978 798 800
    • (1978) Nature , vol.274 , pp. 798-800
    • Balkwill, F.1    Taylor-Papadimitriou, J.2
  • 46
    • 0029997033 scopus 로고    scopus 로고
    • Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest
    • N. Tiefenbrun, D. Melamed, N. Levy, and et al. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest Mol Cell Biol 16 1996 3934 3944
    • (1996) Mol Cell Biol , vol.16 , pp. 3934-3944
    • Tiefenbrun, N.1    Melamed, D.2    Levy, N.3
  • 47
    • 79951740151 scopus 로고    scopus 로고
    • Type I interferon inhibits interleukin-1 production and inflammasome activation
    • G. Guarda, M. Braun, F. Staehli, and et al. Type I interferon inhibits interleukin-1 production and inflammasome activation Immunity 34 2011 213 223
    • (2011) Immunity , vol.34 , pp. 213-223
    • Guarda, G.1    Braun, M.2    Staehli, F.3
  • 48
    • 77951491478 scopus 로고    scopus 로고
    • Recent advances on the immunomodulatory effects of IFN-A: implications for cancer immunotherapy and autoimmunity
    • P. Rizza Recent advances on the immunomodulatory effects of IFN-A: implications for cancer immunotherapy and autoimmunity Autoimmunity 43 2010 204 209
    • (2010) Autoimmunity , vol.43 , pp. 204-209
    • Rizza, P.1
  • 49
    • 77952955507 scopus 로고    scopus 로고
    • Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
    • M. Lu, W. Zhang, Y. Li, and et al. Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway Exp Hematol 38 2010 472 480
    • (2010) Exp Hematol , vol.38 , pp. 472-480
    • Lu, M.1    Zhang, W.2    Li, Y.3
  • 50
    • 0022338499 scopus 로고
    • Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses
    • W. Linkesch, H. Gisslinger, H. Ludwig, and et al. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses] Acta Med Austriaca 12 1985 123 127
    • (1985) Acta Med Austriaca , vol.12 , pp. 123-127
    • Linkesch, W.1    Gisslinger, H.2    Ludwig, H.3
  • 51
    • 0022359194 scopus 로고
    • Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases
    • H. Ludwig, A. Cortelezzi, B.G. Van Camp, and et al. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases Oncology 42 suppl 1 1985 19 25
    • (1985) Oncology , vol.42 , pp. 19-25
    • Ludwig, H.1    Cortelezzi, A.2    Van Camp, B.G.3
  • 52
    • 0023688229 scopus 로고
    • Recombinant interferon-alpha for treatment of polycythaemia vera
    • R.T. Silver Recombinant interferon-alpha for treatment of polycythaemia vera Lancet 2 1988 403
    • (1988) Lancet , vol.2 , pp. 403
    • Silver, R.T.1
  • 53
    • 33746307253 scopus 로고    scopus 로고
    • Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
    • R.T. Silver Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha Cancer 107 2006 451 458
    • (2006) Cancer , vol.107 , pp. 451-458
    • Silver, R.T.1
  • 54
    • 79955947379 scopus 로고    scopus 로고
    • The renaissance of interferon therapy for the treatment of myeloid malignancies
    • J.J. Kiladjian, R.A. Mesa, and R. Hoffman The renaissance of interferon therapy for the treatment of myeloid malignancies Blood 117 2011 4706 4715
    • (2011) Blood , vol.117 , pp. 4706-4715
    • Kiladjian, J.J.1    Mesa, R.A.2    Hoffman, R.3
  • 55
    • 81255210738 scopus 로고    scopus 로고
    • A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
    • H.C. Hasselbalch A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms Expert Rev Hematol 4 2011 637 655
    • (2011) Expert Rev Hematol , vol.4 , pp. 637-655
    • Hasselbalch, H.C.1
  • 56
    • 51549092094 scopus 로고    scopus 로고
    • The impact of PEGylation on biological therapies
    • F.M. Veronese, and A. Mero The impact of PEGylation on biological therapies BioDrugs 22 2008 315 329
    • (2008) BioDrugs , vol.22 , pp. 315-329
    • Veronese, F.M.1    Mero, A.2
  • 57
    • 54049141336 scopus 로고    scopus 로고
    • Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
    • J.J. Kiladjian, B. Cassinat, S. Chevret, and et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera Blood 112 2008 3065 3072
    • (2008) Blood , vol.112 , pp. 3065-3072
    • Kiladjian, J.J.1    Cassinat, B.2    Chevret, S.3
  • 58
    • 84872383163 scopus 로고    scopus 로고
    • Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial
    • P. Turlure, N. Cambier, M. Roussel, and et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial ASH Annual Meeting Abstracts 118 2011 280
    • (2011) ASH Annual Meeting Abstracts , vol.118 , pp. 280
    • Turlure, P.1    Cambier, N.2    Roussel, M.3
  • 59
    • 73949090770 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
    • A. Quintas-Cardama, H. Kantarjian, T. Manshouri, and et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera J Clin Oncol 27 2009 5418 5424
    • (2009) J Clin Oncol , vol.27 , pp. 5418-5424
    • Quintas-Cardama, A.1    Kantarjian, H.2    Manshouri, T.3
  • 60
    • 84883185991 scopus 로고    scopus 로고
    • Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
    • A. Quintás-Cardama, O. Abdel-Wahab, T. Manshouri, and et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a Blood 122 2013 893 901
    • (2013) Blood , vol.122 , pp. 893-901
    • Quintás-Cardama, A.1    Abdel-Wahab, O.2    Manshouri, T.3
  • 61
    • 84867261125 scopus 로고    scopus 로고
    • Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
    • K. Gowin, P. Thapaliya, J. Samuelson, and et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients Haematologica 97 2012 1570 1573
    • (2012) Haematologica , vol.97 , pp. 1570-1573
    • Gowin, K.1    Thapaliya, P.2    Samuelson, J.3
  • 62
    • 0037217859 scopus 로고    scopus 로고
    • Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
    • Y. Alvarado, J. Cortes, S. Verstovsek, and et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia Cancer Chemother Phamacol 51 2003 81 86
    • (2003) Cancer Chemother Phamacol , vol.51 , pp. 81-86
    • Alvarado, Y.1    Cortes, J.2    Verstovsek, S.3
  • 63
    • 33646470836 scopus 로고    scopus 로고
    • A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life
    • J. Samuelsson, H. Hasselbalch, O. Bruserud, and et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life Cancer 106 2006 2397 2405
    • (2006) Cancer , vol.106 , pp. 2397-2405
    • Samuelsson, J.1    Hasselbalch, H.2    Bruserud, O.3
  • 64
    • 35648966599 scopus 로고    scopus 로고
    • PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study
    • E. Jabbour, H. Kantarjian, J. Cortes, and et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study Cancer 110 2007 2012 2018
    • (2007) Cancer , vol.110 , pp. 2012-2018
    • Jabbour, E.1    Kantarjian, H.2    Cortes, J.3
  • 65
    • 84892184457 scopus 로고    scopus 로고
    • AOP2014, a novel peg-proline-interferon alpha-2b with improved pharmacokinetic properties, is safe and well tolerated and shows promising efficacy in patients with polycythemia vera (PV)
    • H. Gisslinger, R. Kralovics, and B. Gisslinger AOP2014, a novel peg-proline-interferon alpha-2b with improved pharmacokinetic properties, is safe and well tolerated and shows promising efficacy in patients with polycythemia vera (PV) Blood 120 suppl 1 2012 175
    • (2012) Blood , vol.120 , pp. 175
    • Gisslinger, H.1    Kralovics, R.2    Gisslinger, B.3
  • 66
    • 20144389274 scopus 로고    scopus 로고
    • Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
    • G. Finazzi, V. Caruso, R. Marchioli, and et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study Blood 105 2005 2664 2670
    • (2005) Blood , vol.105 , pp. 2664-2670
    • Finazzi, G.1    Caruso, V.2    Marchioli, R.3
  • 67
    • 79959203501 scopus 로고    scopus 로고
    • Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
    • M. Bjorkholm, A.R. Derolf, M. Hultcrantz, and et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms J Clin Oncol 29 2011 2410 2415
    • (2011) J Clin Oncol , vol.29 , pp. 2410-2415
    • Bjorkholm, M.1    Derolf, A.R.2    Hultcrantz, M.3
  • 68
    • 84922264206 scopus 로고    scopus 로고
    • Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
    • A. Alvarez-Larrán, L. Martínez-Avilés, J.C. Hernández-Boluda, and et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea Ann Hematol 93 2014 2037 2043
    • (2014) Ann Hematol , vol.93 , pp. 2037-2043
    • Alvarez-Larrán, A.1    Martínez-Avilés, L.2    Hernández-Boluda, J.C.3
  • 69
    • 80053945428 scopus 로고    scopus 로고
    • Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980
    • J.J. Kiladjian, S. Chevret, C. Dosquet, and et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980 J Clin Oncol 29 2011 3907 3913
    • (2011) J Clin Oncol , vol.29 , pp. 3907-3913
    • Kiladjian, J.J.1    Chevret, S.2    Dosquet, C.3
  • 70
    • 84893733177 scopus 로고    scopus 로고
    • A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
    • S. Verstovsek, F. Passamonti, A. Rambaldi, and et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea Cancer 120 2014 513 520
    • (2014) Cancer , vol.120 , pp. 513-520
    • Verstovsek, S.1    Passamonti, F.2    Rambaldi, A.3
  • 71
    • 84939611890 scopus 로고    scopus 로고
    • Ruxolitinib in polycythemia vera resistant to or intolerant of hydroxyurea
    • In press
    • Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib in polycythemia vera resistant to or intolerant of hydroxyurea. N Engl J Med. In press.
    • N Engl J Med
    • Vannucchi, A.M.1    Kiladjian, J.J.2    Griesshammer, M.3
  • 72
    • 84855464431 scopus 로고    scopus 로고
    • Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms
    • V. Skov, T.S. Larsen, M. Thomassen, and et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms Leuk Lymphoma 53 2012 123 129
    • (2012) Leuk Lymphoma , vol.53 , pp. 123-129
    • Skov, V.1    Larsen, T.S.2    Thomassen, M.3
  • 73
    • 33748135979 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules
    • S. Carta, S. Tassi, C. Semino, and et al. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules Blood 108 2006 1618 1626
    • (2006) Blood , vol.108 , pp. 1618-1626
    • Carta, S.1    Tassi, S.2    Semino, C.3
  • 74
    • 34548125345 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
    • J. Golay, L. Cuppini, F. Leoni, and et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells Leukemia 21 2007 1892 1900
    • (2007) Leukemia , vol.21 , pp. 1892-1900
    • Golay, J.1    Cuppini, L.2    Leoni, F.3
  • 75
    • 40749113668 scopus 로고    scopus 로고
    • Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells
    • V. Barbetti, A. Gozzini, E. Rovida, and et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells Oncogene 27 2008 1767 1778
    • (2008) Oncogene , vol.27 , pp. 1767-1778
    • Barbetti, V.1    Gozzini, A.2    Rovida, E.3
  • 76
    • 42349087790 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)
    • V. Guerini, V. Barbui, O. Spinelli, and et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) Leukemia 22 2008 740 747
    • (2008) Leukemia , vol.22 , pp. 740-747
    • Guerini, V.1    Barbui, V.2    Spinelli, O.3
  • 77
    • 77955168425 scopus 로고    scopus 로고
    • A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
    • A. Rambaldi, C.M. Dellacasa, G. Finazzi, and et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Br J Haematol 150 2010 446 455
    • (2010) Br J Haematol , vol.150 , pp. 446-455
    • Rambaldi, A.1    Dellacasa, C.M.2    Finazzi, G.3
  • 78
    • 84877814233 scopus 로고    scopus 로고
    • A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
    • G. Finazzi, A.M. Vannucchi, V. Martinelli, and et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy Br J Haematol 161 2013 688 694
    • (2013) Br J Haematol , vol.161 , pp. 688-694
    • Finazzi, G.1    Vannucchi, A.M.2    Martinelli, V.3
  • 79
    • 84860316991 scopus 로고    scopus 로고
    • Efficacy of vorinostat in a murine model of polycythemia vera
    • H. Akada, S. Akada, A. Gajra, and et al. Efficacy of vorinostat in a murine model of polycythemia vera Blood 119 2012 3779 3789
    • (2012) Blood , vol.119 , pp. 3779-3789
    • Akada, H.1    Akada, S.2    Gajra, A.3
  • 80
    • 84880658117 scopus 로고    scopus 로고
    • A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
    • C.L. Andersen, M.F. McMullin, E. Ejerblad, and et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia Br J Haematol 162 2013 498 508
    • (2013) Br J Haematol , vol.162 , pp. 498-508
    • Andersen, C.L.1    McMullin, M.F.2    Ejerblad, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.